Celgene Stock – Fundamental Analysis
Not enough price data available yet.
Fundamental Data & Ratios (Balance sheet update: 2/28/2019)
| Balance Sheet | Total Assets | 35,480,000,000.00 | ROE | – |
| Balance Sheet | Total Equity | 6,161,000,000.00 | ROA | – |
| Cashflow | Capital Expenditures | -330,000,000.00 | P/FCF | – |
| Cashflow | Free Cash Flow | 4,841,000,000.00 | – | – |
| Cashflow | Operating Cash Flow | 5,171,000,000.00 | P/CF | – |
| Income | Earnings per Share (diluted) | 5.51 | Div. Yield | – |
| Income | Net Income | 4,046,000,000.00 | P/E | – |
| Income | Shares Outstanding | 733,800,000.00 | P/B | – |
| Income | Total Revenue | 15,291,000,000.00 | P/S | – |
Ratios calculated on: –
Company Description
Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. It is engaged in the research and development, which is designed to bring new therapies to market, and is engaged in research in several scientific areas that may deliver therapies, focusing areas, such as intracellular signaling pathways in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies. Its primary commercial stage products include REVLIMID, VIDAZA, THALOMID, ABRAXANE and ISTODAX. Additional sources of revenue include a licensing agreement with Novartis, which entitles it to royalties on FOCALIN XR and the entire RITALIN family of drugs, the sale of services through its Cellular Therapeutics subsidiary and other miscellaneous licensing agreements. In March 2012, it acquired Avila Therapeutics.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.celgene.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more